Advent Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Advent Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$401K	–	235
2024 Q3	$401K	Buy	+10,000	New	+$465K	0.01%	204
2023 Q2	–	Sell	-464	Closed	-$16.6K	–	238
2023 Q1	$16.6K	Hold	464	–	–	﹤0.01%	214
2022 Q4	$17.5K	Hold	464	–	–	﹤0.01%	226
2022 Q3	$21K	Buy	+464	New	+$19.6K	﹤0.01%	218
2013 Q4	–	Hold	0	–	–	–	554
2013 Q3	–	Sell	-14,500	Closed	-$390K	–	597
2013 Q2	$390K	Buy	+14,500	New	+$308K	0.01%	490

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Advent Capital Management's IONS Position: Q4 2024 in Review

Advent Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 10,000 shares — an estimated $401K sold.

Advent Capital Management first reported a position in IONS in Q2 2013 and held it in 5 quarters. The position peaked at $401K in Q3 2024. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

Advent Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Advent Capital Management sold 10,000 Ionis Pharmaceuticals shares in Q4 2024, an estimated $401K.
Advent Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Advent Capital Management's Ionis Pharmaceuticals position peaked at $401K in Q3 2024.
354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Advent Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.